sr141716 has been researched along with transforming growth factor beta in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Deveaux, V; Grenard, P; Julien, B; Ledent, C; Li, L; Lotersztajn, S; Mallat, A; Serriere-Lanneau, V; Teixeira-Clerc, F; Tran Van Nhieu, J | 1 |
| El-Kerdasy, HI; Hussien, NI; Ibrahim, ME | 1 |
2 other study(ies) available for sr141716 and transforming growth factor beta
| Article | Year |
|---|---|
CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis.
Topics: Animals; Cannabinoid Receptor Modulators; Disease Progression; Female; Humans; Liver; Liver Cirrhosis; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Retrospective Studies; Rimonabant; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2006 |
Protective effect of rimonabant, a canabinoid receptor 1 antagonist, on nonalcoholic fatty liver disease in a rat model through modulation of the hepatic expression of activin A and follistatin.
Topics: Activins; Animals; Biomarkers; Cannabinoid Receptor Antagonists; Cytoprotection; Disease Models, Animal; Follistatin; Gene Expression Regulation; Liver; Male; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant; RNA, Messenger; Transforming Growth Factor beta | 2017 |